Business
Full year results
EKF Diagnostics Holdings plc reported full-year results for the year ended 31 December 2025, showing revenues of £51.6 million, a 2.8% increase from £50.2 million in 2024, with gross profit rising to £26.5 million and gross margins improving to 51%. Adjusted EBITDA grew by 9.3% to £12.4 million from £11.3 million, and profit before tax was £7.1 million, up from £6.3 million. The company generated £11.6 million in net cash from operations, and its net cash and cash equivalents stood at £15.8 million. EKF has established a five-year strategic development plan focused on simplification and growth in key product areas, including a 5% increase in its Hematology business and a 10% rise in Beta-Hydroxybutyrate sales within Life Sciences. Disclaimer*
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n\nThis announcement contains inside information\nfor the purposes of UK Market Abuse Regulation.\n \nEKF Diagnostics Holdings plc\n(\"EKF\", the \"Company\" or the \"Group\")\n \nFull year results\n \n9.3% growth in adjusted EBITDA with continued strong cash generation\nEstablishment of five-year strategic development plan for accelerated growth\n \nEKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces its audited results for the year ended 31 December 2025 (\"FY 2025\").\n \nThe 2025 full-year results demonstrate the establishment of EKF's five-year strategic development plan, with a continued focus on simplification of the business, building a strong base for strategically important product groups and services, while moving away from non-core, low margin products.\n \nFinancial highlights\n \n\n\n\n\n· \n\n\nRevenues of £51.6m (2024: £50.2m) - reflecting growth in both point-of-care and Life Sciences\n\n\n\n\n· \n\n\nGross profit (before exceptionals in 2024) of £26.5m (2024: £24.4m)\n\n\n\n\n· \n\n\nGross margins further improvement to 51% (2024: 48%)\n\n\n\n\n· \n\n\nAdjusted EBITDA* up 9.3% to £12.4m (2024: £11.3m)\n\n\n\n\n· \n\n\nProfit before tax of £7.1m (2024: £6.3m)\n\n\n\n\n· \n\n\nNet cash generation from operations of £11.6m (2024: £12.2m)\n\n\n\n\n· \n\n\nNet Cash and cash equivalents as at 31 December 2025 of £15.8m (31 December 2024: £14.3m)\n- £5m returned to shareholders through share buy-backs, continuing into 2026\n- £2.1m held by EKF's Russian subsidiary and subject to regulatory restrictions (31 December 2024: £1.3m)\n\n\n\n\n\n*Earnings before interest, tax, depreciation and amortisation adjusted for exceptional items and share based payments\n \nOperational highlights\n \n\n\n\n\n· \n\n\nBusiness division revenues:\n- Point-of-Care: £33.0m (2024: £31.4m) reflecting improvements in both Hematology and Diabetes\n- Life Sciences: £17.9m (2024: £16.7m) including a 10% rise in β-HB sales\n- Other: (including Discontinued and non-core products*) £0.7m (2024: £2.1m)\n\n\n\n\n· \n\n\nKey strategic go...